FIELD: medicine; pediatrics.
SUBSTANCE: present group of inventions relates to the field of medicine, namely to pediatrics and lung diseases; it is intended for the treatment of developing bronchopulmonary dysplasia (BPD). For the treatment of BPD, a combination of poractant alpha at a dose of 100-200 mg/kg with budesonide at a dose of 0.1-1.5 mg/kg is used. In addition, the use of the above-mentioned combination in the preparation of a drug for the treatment of developing bronchopulmonary dysplasia (BPD), as well as the use of a kit including poractant alpha and budesonide in the above-mentioned dosages for the treatment of developing bronchopulmonary dysplasia (BPD) in premature newborns are presented.
EFFECT: use of the group of inventions provides the possibility of using the combination of poractant alpha with budesonide in the treatment of developing bronchopulmonary dysplasia (BPD).
13 cl, 7 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMBINATION CONTAINING LUNG SURFACTANT AND STEROID | 2010 |
|
RU2533450C2 |
| THERAPEUTIC COMBINATION CONTAINING LUNG SURFACTANT AND ANTIOXIDANT ENZYMES | 2010 |
|
RU2538675C2 |
| RECONSTITUTED PULMONARY SURFACTANTS | 2013 |
|
RU2656185C2 |
| STABLE PHARMACEUTICAL COMPOSITION, INCLUDING REDUCED COMPOSITION OF PULMONARY SURFACTANT | 2017 |
|
RU2748417C2 |
| METHOD FOR PREDICTION OF BRONCHOPULMONARY DYSPLASIA IN NEWBORNS WITH VERY LOW OR EXTREMELY LOW BIRTH BODY WEIGHT | 2012 |
|
RU2504395C1 |
| METHOD OF PREVENTING BRONCHOPULMONARY DYSPLASIA IN NEWBORN BABIES WITH VERY LOW AND EXTREMELY LOW BODY WEIGHT AT BIRTH | 2009 |
|
RU2416388C1 |
| METHOD OF COMPLEX DRUG PREVENTION OF BRONCHOPULMONARY DYSPLASIA IN PRETERM NEWBORN BABIES | 2010 |
|
RU2432953C1 |
| METHOD AND SYSTEM FOR ADMINISTRATION OF PULMONARY SURFACTANT BY ATOMISATION | 2014 |
|
RU2671205C2 |
| DEVICE FOR DRUG DELIVERY INTO LUNG BY MEANS OF CATHETER | 2016 |
|
RU2714183C2 |
| METHOD FOR THERAPY OF PULMONARY DISEASES | 2009 |
|
RU2557048C2 |
